U.S. stock night market volatility: Biodexa Pharmaceuticals fell 8.04% in the night market, market volatility intensified, and capital flow attracted attention

U.S. Stock Night Market Movements Biodexa Pharmaceuticals fell 8.04% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry BeiGene fell 1.73% in the night market. Based on recent key news: On May 4, Wells Fargo announced a target price of $400 per share for BeOne Medicines, which may affect market confidence in the biotechnology sector, leading to a decline in BeiGene's stock price. On May 4, financial reports released by Refinitiv showed that some quarterly performances exceeded expectations, but overall performance was poor, increasing market concerns about future profitability, affecting stock prices. On May 5, Senhwa Biosciences reported that its assets might attract attention from global pharmaceutical companies, enhancing commercial prospects, but failed to immediately boost BeiGene's stock price. The biotechnology sector has been volatile recently and requires attention. Recursion Pharmaceuticals had a trading volume of $211,200, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Amgen fell 0.01% in the night market. Based on recent key news: On May 4, Amgen announced an increase of $300 million in manufacturing investments in the U.S., with total investments nearing $2 billion. This move aims to expand its facilities in Puerto Rico and create hundreds of construction jobs, which may have a positive impact on stock prices. On May 4, Amgen faces competitive pressure in the GLP-1 obesity drug market, leading to its stock performance lagging behind some major competitors, which may negatively impact stock prices. On May 4, BMO Capital analysts maintained a buy rating on Amgen and set a target price of $400, which may provide support for stock prices. Competition in the biotechnology industry is intensifying, with significant capital inflows